Roche issues voluntary recall for Susvimo over manufacturing issue
It’s been almost a year since Roche’s blockbuster ocular implant, the wet age-related macular degeneration (AMD) drug Susvimo, was cleared for twice-annual administration as opposed to monthly injections. Now the company is putting a hold on it.
In the Big Pharma’s Q3 investor call, Roche Pharmaceuticals CEO Bill Anderson said that the company has issued a voluntary recall due to a manufacturing issue. Anderson said in certain cases during reliability testing, it was determined that the septum, or seal on the delivery device, could fail after repeated dosing.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.